ID   SOS1_HUMAN              Reviewed;        1333 AA.
AC   Q07889; A8K2G3; B4DXG2;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JUN-2023, entry version 239.
DE   RecName: Full=Son of sevenless homolog 1;
DE            Short=SOS-1;
GN   Name=SOS1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND INTERACTION WITH
RP   GRB2.
RC   TISSUE=Brain;
RX   PubMed=8493579; DOI=10.1126/science.8493579;
RA   Chardin P., Camonis J.H., Gale N.W., van Aelst L., Wigler M.H.,
RA   Bar-Sagi D.;
RT   "Human Sos1: a guanine nucleotide exchange factor for Ras that binds to
RT   GRB2.";
RL   Science 260:1338-1343(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   IDENTIFICATION IN A COMPLEX WITH MUC1 AND GRB2, AND INTERACTION WITH MUC1.
RX   PubMed=7664271;
RA   Pandey P., Kharbanda S., Kufe D.;
RT   "Association of the DF3/MUC1 breast cancer antigen with Grb2 and the
RT   Sos/Ras exchange protein.";
RL   Cancer Res. 55:4000-4003(1995).
RN   [6]
RP   INTERACTION WITH NCK1 AND NCK2.
RX   PubMed=10026169; DOI=10.1074/jbc.274.9.5542;
RA   Braverman L.E., Quilliam L.A.;
RT   "Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-containing
RT   adapter protein having similar binding and biological properties to Nck.";
RL   J. Biol. Chem. 274:5542-5549(1999).
RN   [7]
RP   INTERACTION WITH LAT2.
RX   PubMed=12486104; DOI=10.1084/jem.20021405;
RA   Brdicka T., Imrich M., Angelisova P., Brdickova N., Horvath O., Spicka J.,
RA   Hilgert I., Luskova P., Draber P., Novak P., Engels N., Wienands J.,
RA   Simeoni L., Oesterreicher J., Aguado E., Malissen M., Schraven B.,
RA   Horejsi V.;
RT   "Non-T cell activation linker (NTAL): a transmembrane adaptor protein
RT   involved in immunoreceptor signaling.";
RL   J. Exp. Med. 196:1617-1626(2002).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF CYS-282.
RX   PubMed=17339331; DOI=10.1128/mcb.01630-06;
RA   Modzelewska K., Elgort M.G., Huang J., Jongeward G., Lauritzen A.,
RA   Yoon C.H., Sternberg P.W., Moghal N.;
RT   "An activating mutation in sos-1 identifies its Dbl domain as a critical
RT   inhibitor of the epidermal growth factor receptor pathway during
RT   Caenorhabditis elegans vulval development.";
RL   Mol. Cell. Biol. 27:3695-3707(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1134, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1134, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   PHOSPHORYLATION AT SER-1134 AND SER-1161, MUTAGENESIS OF SER-1134 AND
RP   SER-1161, AND INTERACTION WITH YWHAB AND YWHAE.
RX   PubMed=22827337; DOI=10.1042/bj20120938;
RA   Saha M., Carriere A., Cheerathodi M., Zhang X., Lavoie G., Rush J.,
RA   Roux P.P., Ballif B.A.;
RT   "RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively
RT   regulating MAPK activation.";
RL   Biochem. J. 447:159-166(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1082; SER-1134; SER-1178;
RP   SER-1210; SER-1229 AND SER-1275, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1082 AND SER-1275, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   STRUCTURE BY NMR OF 422-551.
RX   PubMed=9374522; DOI=10.1074/jbc.272.48.30340;
RA   Zheng J., Chen R.H., Corblan-Garcia S., Cahill S.M., Bar-Sagi D.,
RA   Cowburn D.;
RT   "The solution structure of the pleckstrin homology domain of human SOS1. A
RT   possible structural role for the sequential association of diffuse B cell
RT   lymphoma and pleckstrin homology domains.";
RL   J. Biol. Chem. 272:30340-30344(1997).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 198-551.
RX   PubMed=9790532; DOI=10.1016/s0092-8674(00)81756-0;
RA   Soisson S.M., Nimnual A.S., Uy M., Bar-Sagi D., Kuriyan J.;
RT   "Crystal structure of the Dbl and pleckstrin homology domains from the
RT   human Son of sevenless protein.";
RL   Cell 95:259-268(1998).
RN   [19]
RP   INVOLVEMENT IN GINGF1, AND TISSUE SPECIFICITY.
RX   PubMed=11868160; DOI=10.1086/339689;
RA   Hart T.C., Zhang Y., Gorry M.C., Hart P.S., Cooper M., Marazita M.L.,
RA   Marks J.M., Cortelli J.R., Pallos D.;
RT   "A mutation in the SOS1 gene causes hereditary gingival fibromatosis type
RT   1.";
RL   Am. J. Hum. Genet. 70:943-954(2002).
RN   [20]
RP   VARIANTS NS4 LYS-266; ARG-269; TYR-309; CYS-337; ARG-434; ARG-548; GLY-552
RP   AND LYS-846, AND VARIANT LEU-655.
RX   PubMed=17143285; DOI=10.1038/ng1926;
RA   Roberts A.E., Araki T., Swanson K.D., Montgomery K.T., Schiripo T.A.,
RA   Joshi V.A., Li L., Yassin Y., Tamburino A.M., Neel B.G., Kucherlapati R.S.;
RT   "Germline gain-of-function mutations in SOS1 cause Noonan syndrome.";
RL   Nat. Genet. 39:70-74(2007).
RN   [21]
RP   VARIANTS NS4 LYS-108; ARG-269; ARG-432; LYS-433; TYR-441; ARG-548; PRO-550;
RP   GLY-552; LYS-552; SER-552; HIS-702; LEU-729; PHE-733 AND LYS-846, VARIANTS
RP   LEU-655; ARG-977 AND ARG-1320, AND CHARACTERIZATION OF VARIANTS NS4 GLY-552
RP   AND LEU-729.
RX   PubMed=17143282; DOI=10.1038/ng1939;
RA   Tartaglia M., Pennacchio L.A., Zhao C., Yadav K.K., Fodale V., Sarkozy A.,
RA   Pandit B., Oishi K., Martinelli S., Schackwitz W., Ustaszewska A.,
RA   Martin J., Bristow J., Carta C., Lepri F., Neri C., Vasta I., Gibson K.,
RA   Curry C.J., Lopez Siguero J.P., Digilio M.C., Zampino G., Dallapiccola B.,
RA   Bar-Sagi D., Gelb B.D.;
RT   "Gain-of-function SOS1 mutations cause a distinctive form of Noonan
RT   syndrome.";
RL   Nat. Genet. 39:75-79(2007).
RN   [22]
RP   VARIANT NS4 GLU-170.
RX   PubMed=19020799; DOI=10.1007/s10038-008-0343-6;
RA   Ko J.M., Kim J.M., Kim G.H., Yoo H.W.;
RT   "PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype
RT   correlation in Korean patients with Noonan syndrome.";
RL   J. Hum. Genet. 53:999-1006(2008).
RN   [23]
RP   VARIANT NS4 ARG-432.
RX   PubMed=19438935; DOI=10.1111/j.1399-0004.2009.01149.x;
RA   Hanna N., Parfait B., Talaat I.M., Vidaud M., Elsedfy H.H.;
RT   "SOS1: a new player in the Noonan-like/multiple giant cell lesion
RT   syndrome.";
RL   Clin. Genet. 75:568-571(2009).
RN   [24]
RP   VARIANTS NS4 THR-269; ARG-477 AND HIS-702, VARIANT GLN-497, AND
RP   CHARACTERIZATION OF VARIANT GLN-497.
RX   PubMed=20683980; DOI=10.1002/ajmg.a.33564;
RA   Longoni M., Moncini S., Cisternino M., Morella I.M., Ferraiuolo S.,
RA   Russo S., Mannarino S., Brazzelli V., Coi P., Zippel R., Venturin M.,
RA   Riva P.;
RT   "Noonan syndrome associated with both a new Jnk-activating familial SOS1
RT   and a de novo RAF1 mutations.";
RL   Am. J. Med. Genet. A 152:2176-2184(2010).
RN   [25]
RP   VARIANT NS4 ILE-623.
RX   PubMed=20673819; DOI=10.1016/j.ejmg.2010.07.011;
RA   Fabretto A., Kutsche K., Harmsen M.B., Demarini S., Gasparini P.,
RA   Fertz M.C., Zenker M.;
RT   "Two cases of Noonan syndrome with severe respiratory and gastroenteral
RT   involvement and the SOS1 mutation F623I.";
RL   Eur. J. Med. Genet. 53:322-324(2010).
RN   [26]
RP   VARIANTS NS4 ARG-102; GLU-170; LYS-266; THR-269; ALA-378; LYS-433 AND
RP   GLY-552, AND VARIANTS VAL-569 AND LEU-655.
RX   PubMed=19953625; DOI=10.1002/gcc.20735;
RA   Denayer E., Devriendt K., de Ravel T., Van Buggenhout G., Smeets E.,
RA   Francois I., Sznajer Y., Craen M., Leventopoulos G., Mutesa L.,
RA   Vandecasseye W., Massa G., Kayserili H., Sciot R., Fryns J.P., Legius E.;
RT   "Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1
RT   mutations.";
RL   Genes Chromosomes Cancer 49:242-252(2010).
RN   [27]
RP   VARIANTS NS4 LYS-108; ARG-112; GLU-170; THR-252; LYS-266; THR-269; ARG-269;
RP   VAL-422; LYS-424; 427-LYS--ASP-430 DELINS ASN; ARG-432; 432-TRP-GLU-433
RP   DEL; LYS-433; ARG-434; LYS-434; THR-437; TYR-441; ARG-477; ARG-478;
RP   ARG-482; ARG-490; GLN-497; ARG-548; LYS-549; GLY-552; LYS-552; MET-552;
RP   THR-552; SER-552; 554-LEU--MET-558 DELINS LYS; PHE-733; LYS-846 AND
RP   ARG-894, AND VARIANTS ALA-37; LEU-478; VAL-569; LEU-655; THR-708; THR-784;
RP   SER-1011; LYS-1131; ILE-1140; ALA-1257 AND ARG-1320.
RX   PubMed=21387466; DOI=10.1002/humu.21492;
RA   Lepri F., De Luca A., Stella L., Rossi C., Baldassarre G., Pantaleoni F.,
RA   Cordeddu V., Williams B.J., Dentici M.L., Caputo V., Venanzi S.,
RA   Bonaguro M., Kavamura I., Faienza M.F., Pilotta A., Stanzial F.,
RA   Faravelli F., Gabrielli O., Marino B., Neri G., Silengo M.C., Ferrero G.B.,
RA   Torrrente I., Selicorni A., Mazzanti L., Digilio M.C., Zampino G.,
RA   Dallapiccola B., Gelb B.D., Tartaglia M.;
RT   "SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights
RT   on pathogenic effects, and genotype-phenotype correlations.";
RL   Hum. Mutat. 32:760-772(2011).
CC   -!- FUNCTION: Promotes the exchange of Ras-bound GDP by GTP
CC       (PubMed:8493579). Probably by promoting Ras activation, regulates
CC       phosphorylation of MAP kinase MAPK3 in response to EGF
CC       (PubMed:17339331). Catalytic component of a trimeric complex that
CC       participates in transduction of signals from Ras to Rac by promoting
CC       the Rac-specific guanine nucleotide exchange factor (GEF) activity (By
CC       similarity). {ECO:0000250|UniProtKB:Q62245,
CC       ECO:0000269|PubMed:17339331, ECO:0000269|PubMed:8493579}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with GRB2 (via SH3 domain)
CC       (PubMed:8493579, PubMed:7664271). Forms a complex with phosphorylated
CC       MUC1 and GRB2 (via its SH3 domains) (PubMed:7664271). Interacts with
CC       phosphorylated LAT2 (PubMed:12486104). Interacts with NCK1 and NCK2
CC       (PubMed:10026169). Part of a complex consisting of ABI1, EPS8 and SOS1
CC       (By similarity). Interacts (Ser-1134 and Ser-1161 phosphorylated form)
CC       with YWHAB and YWHAE (PubMed:22827337). {ECO:0000250|UniProtKB:Q62245,
CC       ECO:0000269|PubMed:10026169, ECO:0000269|PubMed:12486104,
CC       ECO:0000269|PubMed:22827337, ECO:0000269|PubMed:7664271,
CC       ECO:0000269|PubMed:8493579}.
CC   -!- INTERACTION:
CC       Q07889; Q9UNS2: COPS3; NbExp=3; IntAct=EBI-297487, EBI-350590;
CC       Q07889; P46108: CRK; NbExp=7; IntAct=EBI-297487, EBI-886;
CC       Q07889; P00533: EGFR; NbExp=2; IntAct=EBI-297487, EBI-297353;
CC       Q07889; P62993: GRB2; NbExp=26; IntAct=EBI-297487, EBI-401755;
CC       Q07889; P08631: HCK; NbExp=4; IntAct=EBI-297487, EBI-346340;
CC       Q07889; P01112: HRAS; NbExp=11; IntAct=EBI-297487, EBI-350145;
CC       Q07889; P16333: NCK1; NbExp=5; IntAct=EBI-297487, EBI-389883;
CC       Q07889; P20929: NEB; NbExp=3; IntAct=EBI-297487, EBI-1049657;
CC       Q07889; Q9UKS6: PACSIN3; NbExp=2; IntAct=EBI-297487, EBI-77926;
CC       Q07889; P27986: PIK3R1; NbExp=3; IntAct=EBI-297487, EBI-79464;
CC       Q07889; P19174: PLCG1; NbExp=3; IntAct=EBI-297487, EBI-79387;
CC       Q07889; P29353: SHC1; NbExp=2; IntAct=EBI-297487, EBI-78835;
CC       Q07889; Q9Y5X1: SNX9; NbExp=2; IntAct=EBI-297487, EBI-77848;
CC       Q07889; P57075-2: UBASH3A; NbExp=3; IntAct=EBI-297487, EBI-7353612;
CC       Q07889; Q5TCZ1-2; NbExp=5; IntAct=EBI-297487, EBI-7014859;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q07889-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q07889-2; Sequence=VSP_056463, VSP_056464, VSP_056465;
CC   -!- TISSUE SPECIFICITY: Expressed in gingival tissues.
CC       {ECO:0000269|PubMed:11868160}.
CC   -!- PTM: Phosphorylation at Ser-1134 and Ser-1161 by RPS6KA3 create YWHAB
CC       and YWHAE binding sites and which contribute to the negative regulation
CC       of EGF-induced MAPK1/3 phosphorylation. {ECO:0000269|PubMed:22827337}.
CC   -!- DISEASE: Fibromatosis, gingival, 1 (GINGF1) [MIM:135300]: A form of
CC       hereditary gingival fibromatosis, a rare condition characterized by a
CC       slow, progressive overgrowth of the gingiva. The excess gingival tissue
CC       can cover part of or the entire crown, and can result in diastemas,
CC       teeth displacement, or retention of primary or impacted teeth. GINGF1
CC       is usually transmitted as an autosomal dominant trait, although
CC       sporadic cases are common. {ECO:0000269|PubMed:11868160}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Noonan syndrome 4 (NS4) [MIM:610733]: A form of Noonan
CC       syndrome, a disease characterized by short stature, facial dysmorphic
CC       features such as hypertelorism, a downward eyeslant and low-set
CC       posteriorly rotated ears, and a high incidence of congenital heart
CC       defects and hypertrophic cardiomyopathy. Other features can include a
CC       short neck with webbing or redundancy of skin, deafness, motor delay,
CC       variable intellectual deficits, multiple skeletal defects,
CC       cryptorchidism, and bleeding diathesis. Individuals with Noonan
CC       syndrome are at risk of juvenile myelomonocytic leukemia, a
CC       myeloproliferative disorder characterized by excessive production of
CC       myelomonocytic cells. Some patients with NS4 have polyarticular
CC       villonodular synovitis. {ECO:0000269|PubMed:17143282,
CC       ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19020799,
CC       ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:19953625,
CC       ECO:0000269|PubMed:20673819, ECO:0000269|PubMed:20683980,
CC       ECO:0000269|PubMed:21387466}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Son of sevenless entry;
CC       URL="https://en.wikipedia.org/wiki/Son_of_Sevenless";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L13857; AAA35913.1; -; mRNA.
DR   EMBL; AK290228; BAF82917.1; -; mRNA.
DR   EMBL; AK301960; BAG63374.1; -; mRNA.
DR   EMBL; AC019171; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092672; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471053; EAX00351.1; -; Genomic_DNA.
DR   CCDS; CCDS1802.1; -. [Q07889-1]
DR   PIR; A37488; A37488.
DR   RefSeq; NP_005624.2; NM_005633.3. [Q07889-1]
DR   PDB; 1AWE; NMR; -; A=422-551.
DR   PDB; 1BKD; X-ray; 2.80 A; S=568-1044.
DR   PDB; 1DBH; X-ray; 2.30 A; A=198-551.
DR   PDB; 1NVU; X-ray; 2.20 A; S=566-1046.
DR   PDB; 1NVV; X-ray; 2.18 A; S=566-1046.
DR   PDB; 1NVW; X-ray; 2.70 A; S=566-1046.
DR   PDB; 1NVX; X-ray; 3.20 A; S=566-1046.
DR   PDB; 1Q9C; X-ray; 3.21 A; A/B/C/D/E/F/G/H/I=1-191.
DR   PDB; 1XD2; X-ray; 2.70 A; C=566-1049.
DR   PDB; 1XD4; X-ray; 3.64 A; A/B=198-1049.
DR   PDB; 1XDV; X-ray; 4.10 A; A/B=198-1044.
DR   PDB; 2II0; X-ray; 2.02 A; A=564-1049.
DR   PDB; 3KSY; X-ray; 3.18 A; A=1-1049.
DR   PDB; 4NYI; X-ray; 2.96 A; S=566-1046.
DR   PDB; 4NYJ; X-ray; 2.85 A; S=566-1046.
DR   PDB; 4NYM; X-ray; 3.55 A; S=566-1046.
DR   PDB; 4URU; X-ray; 2.83 A; S=564-1049.
DR   PDB; 4URV; X-ray; 2.58 A; S=564-1049.
DR   PDB; 4URW; X-ray; 2.76 A; S=564-1049.
DR   PDB; 4URX; X-ray; 2.49 A; S=564-1049.
DR   PDB; 4URY; X-ray; 2.47 A; S=564-1049.
DR   PDB; 4URZ; X-ray; 2.24 A; S=564-1049.
DR   PDB; 4US0; X-ray; 2.17 A; S=564-1049.
DR   PDB; 4US1; X-ray; 2.65 A; S=564-1049.
DR   PDB; 4US2; X-ray; 2.48 A; S=564-1049.
DR   PDB; 5OVD; X-ray; 1.90 A; A=560-1049.
DR   PDB; 5OVE; X-ray; 1.85 A; A=560-1049.
DR   PDB; 5OVF; X-ray; 2.01 A; A=560-1049.
DR   PDB; 5OVG; X-ray; 2.30 A; A=560-1049.
DR   PDB; 5OVH; X-ray; 2.30 A; A=560-1049.
DR   PDB; 5OVI; X-ray; 2.20 A; A=560-1049.
DR   PDB; 5WFO; X-ray; 1.99 A; N=566-1046.
DR   PDB; 5WFP; X-ray; 2.08 A; N=566-1046.
DR   PDB; 5WFQ; X-ray; 2.26 A; N=566-1046.
DR   PDB; 5WFR; X-ray; 2.46 A; N=566-1046.
DR   PDB; 6BVI; X-ray; 1.75 A; B=566-1046.
DR   PDB; 6BVJ; X-ray; 1.75 A; B=566-1046.
DR   PDB; 6BVK; X-ray; 1.80 A; B=566-1046.
DR   PDB; 6BVL; X-ray; 1.75 A; B=566-1046.
DR   PDB; 6BVM; X-ray; 1.80 A; B=566-1046.
DR   PDB; 6CUO; X-ray; 1.73 A; B=566-1046.
DR   PDB; 6CUP; X-ray; 1.83 A; B=566-1046.
DR   PDB; 6CUR; X-ray; 1.73 A; B=566-1046.
DR   PDB; 6D55; X-ray; 1.68 A; B=566-1046.
DR   PDB; 6D56; X-ray; 1.68 A; B=566-1046.
DR   PDB; 6D59; X-ray; 1.70 A; B=566-1046.
DR   PDB; 6D5E; X-ray; 1.75 A; B=566-1046.
DR   PDB; 6D5G; X-ray; 1.92 A; B=566-1046.
DR   PDB; 6D5H; X-ray; 1.80 A; B=566-1046.
DR   PDB; 6D5J; X-ray; 1.75 A; B=566-1046.
DR   PDB; 6D5L; X-ray; 1.70 A; B=566-1046.
DR   PDB; 6D5M; X-ray; 2.08 A; S=566-1046.
DR   PDB; 6D5V; X-ray; 2.04 A; S=566-1046.
DR   PDB; 6D5W; X-ray; 2.48 A; S=566-1046.
DR   PDB; 6EPL; X-ray; 2.55 A; S=563-1049.
DR   PDB; 6EPM; X-ray; 2.50 A; S=563-1049.
DR   PDB; 6EPN; X-ray; 2.50 A; S=563-1049.
DR   PDB; 6EPO; X-ray; 2.40 A; S=563-1049.
DR   PDB; 6EPP; X-ray; 2.40 A; S=563-1049.
DR   PDB; 6F08; X-ray; 1.90 A; D/K/N/Q=1155-1167.
DR   PDB; 6SCM; X-ray; 1.87 A; A=564-1049.
DR   PDB; 6SFR; X-ray; 1.92 A; A/B=564-1049.
DR   PDB; 6V94; X-ray; 1.80 A; B=566-1046.
DR   PDB; 6V9F; X-ray; 1.85 A; B=566-1046.
DR   PDB; 6V9J; X-ray; 1.76 A; B=566-1046.
DR   PDB; 6V9L; X-ray; 1.70 A; B=566-1046.
DR   PDB; 6V9M; X-ray; 1.65 A; B=566-1046.
DR   PDB; 6V9N; X-ray; 1.65 A; B=566-1046.
DR   PDB; 6V9O; X-ray; 1.80 A; B=566-1046.
DR   PDB; 6Y44; X-ray; 1.71 A; P=1155-1167.
DR   PDB; 7AVI; X-ray; 1.93 A; A/B=564-1049.
DR   PDB; 7AVL; X-ray; 1.72 A; A/B=564-1049.
DR   PDB; 7AVS; X-ray; 2.28 A; A/B=564-1049.
DR   PDB; 7AVT; X-ray; 1.88 A; A/B=564-1049.
DR   PDB; 7AVU; X-ray; 2.10 A; A/B=564-1049.
DR   PDB; 7AVV; X-ray; 2.12 A; A=564-1049.
DR   PDB; 7KFZ; EM; 3.47 A; B=564-1049.
DR   PDB; 7UKR; X-ray; 2.50 A; A/B=564-1049.
DR   PDB; 7UKS; X-ray; 2.29 A; A=564-1049.
DR   PDBsum; 1AWE; -.
DR   PDBsum; 1BKD; -.
DR   PDBsum; 1DBH; -.
DR   PDBsum; 1NVU; -.
DR   PDBsum; 1NVV; -.
DR   PDBsum; 1NVW; -.
DR   PDBsum; 1NVX; -.
DR   PDBsum; 1Q9C; -.
DR   PDBsum; 1XD2; -.
DR   PDBsum; 1XD4; -.
DR   PDBsum; 1XDV; -.
DR   PDBsum; 2II0; -.
DR   PDBsum; 3KSY; -.
DR   PDBsum; 4NYI; -.
DR   PDBsum; 4NYJ; -.
DR   PDBsum; 4NYM; -.
DR   PDBsum; 4URU; -.
DR   PDBsum; 4URV; -.
DR   PDBsum; 4URW; -.
DR   PDBsum; 4URX; -.
DR   PDBsum; 4URY; -.
DR   PDBsum; 4URZ; -.
DR   PDBsum; 4US0; -.
DR   PDBsum; 4US1; -.
DR   PDBsum; 4US2; -.
DR   PDBsum; 5OVD; -.
DR   PDBsum; 5OVE; -.
DR   PDBsum; 5OVF; -.
DR   PDBsum; 5OVG; -.
DR   PDBsum; 5OVH; -.
DR   PDBsum; 5OVI; -.
DR   PDBsum; 5WFO; -.
DR   PDBsum; 5WFP; -.
DR   PDBsum; 5WFQ; -.
DR   PDBsum; 5WFR; -.
DR   PDBsum; 6BVI; -.
DR   PDBsum; 6BVJ; -.
DR   PDBsum; 6BVK; -.
DR   PDBsum; 6BVL; -.
DR   PDBsum; 6BVM; -.
DR   PDBsum; 6CUO; -.
DR   PDBsum; 6CUP; -.
DR   PDBsum; 6CUR; -.
DR   PDBsum; 6D55; -.
DR   PDBsum; 6D56; -.
DR   PDBsum; 6D59; -.
DR   PDBsum; 6D5E; -.
DR   PDBsum; 6D5G; -.
DR   PDBsum; 6D5H; -.
DR   PDBsum; 6D5J; -.
DR   PDBsum; 6D5L; -.
DR   PDBsum; 6D5M; -.
DR   PDBsum; 6D5V; -.
DR   PDBsum; 6D5W; -.
DR   PDBsum; 6EPL; -.
DR   PDBsum; 6EPM; -.
DR   PDBsum; 6EPN; -.
DR   PDBsum; 6EPO; -.
DR   PDBsum; 6EPP; -.
DR   PDBsum; 6F08; -.
DR   PDBsum; 6SCM; -.
DR   PDBsum; 6SFR; -.
DR   PDBsum; 6V94; -.
DR   PDBsum; 6V9F; -.
DR   PDBsum; 6V9J; -.
DR   PDBsum; 6V9L; -.
DR   PDBsum; 6V9M; -.
DR   PDBsum; 6V9N; -.
DR   PDBsum; 6V9O; -.
DR   PDBsum; 6Y44; -.
DR   PDBsum; 7AVI; -.
DR   PDBsum; 7AVL; -.
DR   PDBsum; 7AVS; -.
DR   PDBsum; 7AVT; -.
DR   PDBsum; 7AVU; -.
DR   PDBsum; 7AVV; -.
DR   PDBsum; 7KFZ; -.
DR   PDBsum; 7UKR; -.
DR   PDBsum; 7UKS; -.
DR   AlphaFoldDB; Q07889; -.
DR   SMR; Q07889; -.
DR   BioGRID; 112537; 80.
DR   ComplexPortal; CPX-395; GTPase HRAS - Son of sevenless homolog 1 complex.
DR   CORUM; Q07889; -.
DR   DIP; DIP-31802N; -.
DR   IntAct; Q07889; 43.
DR   MINT; Q07889; -.
DR   STRING; 9606.ENSP00000387784; -.
DR   BindingDB; Q07889; -.
DR   ChEMBL; CHEMBL2079846; -.
DR   GuidetoPHARMACOLOGY; 3096; -.
DR   GlyGen; Q07889; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q07889; -.
DR   PhosphoSitePlus; Q07889; -.
DR   BioMuta; SOS1; -.
DR   DMDM; 6094322; -.
DR   CPTAC; CPTAC-1554; -.
DR   CPTAC; CPTAC-1555; -.
DR   EPD; Q07889; -.
DR   jPOST; Q07889; -.
DR   MassIVE; Q07889; -.
DR   MaxQB; Q07889; -.
DR   PaxDb; Q07889; -.
DR   PeptideAtlas; Q07889; -.
DR   ProteomicsDB; 5432; -.
DR   ProteomicsDB; 58554; -. [Q07889-1]
DR   Antibodypedia; 2769; 259 antibodies from 36 providers.
DR   DNASU; 6654; -.
DR   Ensembl; ENST00000402219.8; ENSP00000384675.2; ENSG00000115904.15. [Q07889-1]
DR   GeneID; 6654; -.
DR   KEGG; hsa:6654; -.
DR   MANE-Select; ENST00000402219.8; ENSP00000384675.2; NM_005633.4; NP_005624.2.
DR   UCSC; uc002rrk.5; human. [Q07889-1]
DR   AGR; HGNC:11187; -.
DR   CTD; 6654; -.
DR   DisGeNET; 6654; -.
DR   GeneCards; SOS1; -.
DR   GeneReviews; SOS1; -.
DR   HGNC; HGNC:11187; SOS1.
DR   HPA; ENSG00000115904; Low tissue specificity.
DR   MalaCards; SOS1; -.
DR   MIM; 135300; phenotype.
DR   MIM; 182530; gene.
DR   MIM; 610733; phenotype.
DR   neXtProt; NX_Q07889; -.
DR   OpenTargets; ENSG00000115904; -.
DR   Orphanet; 2024; Hereditary gingival fibromatosis.
DR   Orphanet; 648; Noonan syndrome.
DR   PharmGKB; PA36024; -.
DR   VEuPathDB; HostDB:ENSG00000115904; -.
DR   eggNOG; KOG3417; Eukaryota.
DR   GeneTree; ENSGT00940000155423; -.
DR   InParanoid; Q07889; -.
DR   OMA; FREPFIS; -.
DR   OrthoDB; 68574at2759; -.
DR   PhylomeDB; Q07889; -.
DR   TreeFam; TF317296; -.
DR   PathwayCommons; Q07889; -.
DR   Reactome; R-HSA-112412; SOS-mediated signalling.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-167044; Signalling to RAS.
DR   Reactome; R-HSA-179812; GRB2 events in EGFR signaling.
DR   Reactome; R-HSA-180336; SHC1 events in EGFR signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-193648; NRAGE signals death through JNK.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-428540; Activation of RAC1.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2.
DR   Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling.
DR   Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3.
DR   Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling.
DR   Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling.
DR   Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4.
DR   Reactome; R-HSA-5655253; Signaling by FGFR2 in disease.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-5655332; Signaling by FGFR3 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-74749; Signal attenuation.
DR   Reactome; R-HSA-74751; Insulin receptor signalling cascade.
DR   Reactome; R-HSA-8851805; MET activates RAS signaling.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-8983432; Interleukin-15 signaling.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS.
DR   Reactome; R-HSA-9027284; Erythropoietin activates RAS.
DR   Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3.
DR   Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-9607240; FLT3 Signaling.
DR   Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2.
DR   Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants.
DR   Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants.
DR   Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants.
DR   Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants.
DR   Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants.
DR   Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells.
DR   Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins.
DR   Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; Q07889; -.
DR   SIGNOR; Q07889; -.
DR   BioGRID-ORCS; 6654; 117 hits in 1167 CRISPR screens.
DR   ChiTaRS; SOS1; human.
DR   EvolutionaryTrace; Q07889; -.
DR   GeneWiki; SOS1; -.
DR   GenomeRNAi; 6654; -.
DR   Pharos; Q07889; Tchem.
DR   PRO; PR:Q07889; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q07889; protein.
DR   Bgee; ENSG00000115904; Expressed in colonic epithelium and 210 other tissues.
DR   ExpressionAtlas; Q07889; baseline and differential.
DR   Genevisible; Q07889; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:CAFA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:1905360; C:GTPase complex; IPI:ComplexPortal.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0005096; F:GTPase activator activity; TAS:ProtInc.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; EXP:Reactome.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048514; P:blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0003209; P:cardiac atrium morphogenesis; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0061029; P:eyelid development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0001942; P:hair follicle development; IEA:Ensembl.
DR   GO; GO:0061384; P:heart trabecula morphogenesis; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:1904693; P:midbrain morphogenesis; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0003344; P:pericardium morphogenesis; IEA:Ensembl.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IBA:GO_Central.
DR   GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; IEA:Ensembl.
DR   GO; GO:0007265; P:Ras protein signal transduction; IDA:ComplexPortal.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IDA:ComplexPortal.
DR   GO; GO:0043405; P:regulation of MAP kinase activity; IDA:ComplexPortal.
DR   GO; GO:2000973; P:regulation of pro-B cell differentiation; IEA:Ensembl.
DR   GO; GO:0033081; P:regulation of T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0042129; P:regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0060021; P:roof of mouth development; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   GO; GO:0007296; P:vitellogenesis; IEA:Ensembl.
DR   CDD; cd01261; PH_SOS; 1.
DR   CDD; cd00155; RasGEF; 1.
DR   CDD; cd06224; REM; 1.
DR   CDD; cd00160; RhoGEF; 1.
DR   DisProt; DP01534; -.
DR   Gene3D; 6.10.250.3060; -; 1.
DR   Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1.
DR   Gene3D; 1.10.20.10; Histone, subunit A; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 1.10.840.10; Ras guanine-nucleotide exchange factors catalytic domain; 1.
DR   Gene3D; 1.20.870.10; Son of sevenless (SoS) protein Chain: S domain 1; 1.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR009072; Histone-fold.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR008937; Ras-like_GEF.
DR   InterPro; IPR000651; Ras-like_Gua-exchang_fac_N.
DR   InterPro; IPR019804; Ras_G-nucl-exch_fac_CS.
DR   InterPro; IPR023578; Ras_GEF_dom_sf.
DR   InterPro; IPR001895; RASGEF_cat_dom.
DR   InterPro; IPR036964; RASGEF_cat_dom_sf.
DR   PANTHER; PTHR23113; GUANINE NUCLEOTIDE EXCHANGE FACTOR; 1.
DR   PANTHER; PTHR23113:SF168; SON OF SEVENLESS HOMOLOG 1; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00617; RasGEF; 1.
DR   Pfam; PF00618; RasGEF_N; 1.
DR   Pfam; PF00621; RhoGEF; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00147; RasGEF; 1.
DR   SMART; SM00229; RasGEFN; 1.
DR   SMART; SM00325; RhoGEF; 1.
DR   SUPFAM; SSF48065; DBL homology domain (DH-domain); 1.
DR   SUPFAM; SSF47113; Histone-fold; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF48366; Ras GEF; 1.
DR   PROSITE; PS50010; DH_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00720; RASGEF; 1.
DR   PROSITE; PS50009; RASGEF_CAT; 1.
DR   PROSITE; PS50212; RASGEF_NTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Disease variant;
KW   Guanine-nucleotide releasing factor; Phosphoprotein; Reference proteome.
FT   CHAIN           1..1333
FT                   /note="Son of sevenless homolog 1"
FT                   /id="PRO_0000068894"
FT   DOMAIN          200..390
FT                   /note="DH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          444..548
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          597..741
FT                   /note="N-terminal Ras-GEF"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00135"
FT   DOMAIN          780..1019
FT                   /note="Ras-GEF"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00168"
FT   REGION          1019..1103
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1129..1333
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1129..1143
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1147..1161
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1190..1206
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1252..1271
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1306..1321
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1078
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62245"
FT   MOD_RES         1082
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1134
FT                   /note="Phosphoserine; by RPS6KA3"
FT                   /evidence="ECO:0000269|PubMed:22827337,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1161
FT                   /note="Phosphoserine; by RPS6KA3"
FT                   /evidence="ECO:0000269|PubMed:22827337"
FT   MOD_RES         1178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1210
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1229
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1275
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         1..57
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056463"
FT   VAR_SEQ         359..371
FT                   /note="QLEEKSEDQEDKE -> FPFGDLSRLRDSV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056464"
FT   VAR_SEQ         372..1333
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056465"
FT   VARIANT         37
FT                   /note="T -> A (in a patient with Noonan syndrome;
FT                   dbSNP:rs150565592)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066031"
FT   VARIANT         102
FT                   /note="P -> R (in NS4; dbSNP:rs1553362937)"
FT                   /evidence="ECO:0000269|PubMed:19953625"
FT                   /id="VAR_066032"
FT   VARIANT         108
FT                   /note="E -> K (in NS4; dbSNP:rs397517164)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030423"
FT   VARIANT         112
FT                   /note="P -> R (in NS4; dbSNP:rs397517166)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066033"
FT   VARIANT         170
FT                   /note="K -> E (in NS4; dbSNP:rs397517172)"
FT                   /evidence="ECO:0000269|PubMed:19020799,
FT                   ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066034"
FT   VARIANT         252
FT                   /note="I -> T (in NS4; dbSNP:rs142094234)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066035"
FT   VARIANT         266
FT                   /note="T -> K (in NS4; dbSNP:rs137852812)"
FT                   /evidence="ECO:0000269|PubMed:17143285,
FT                   ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030424"
FT   VARIANT         269
FT                   /note="M -> R (in NS4; dbSNP:rs137852813)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030425"
FT   VARIANT         269
FT                   /note="M -> T (in NS4; dbSNP:rs137852813)"
FT                   /evidence="ECO:0000269|PubMed:19953625,
FT                   ECO:0000269|PubMed:20683980, ECO:0000269|PubMed:21387466"
FT                   /id="VAR_064504"
FT   VARIANT         309
FT                   /note="D -> Y (in NS4; dbSNP:rs397517180)"
FT                   /evidence="ECO:0000269|PubMed:17143285"
FT                   /id="VAR_030426"
FT   VARIANT         337
FT                   /note="Y -> C (in NS4; dbSNP:rs724160007)"
FT                   /evidence="ECO:0000269|PubMed:17143285"
FT                   /id="VAR_030427"
FT   VARIANT         378
FT                   /note="T -> A (in NS4; dbSNP:rs397517146)"
FT                   /evidence="ECO:0000269|PubMed:19953625"
FT                   /id="VAR_066036"
FT   VARIANT         422
FT                   /note="M -> V (in NS4)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066037"
FT   VARIANT         424
FT                   /note="E -> K (in NS4; dbSNP:rs730881041)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066038"
FT   VARIANT         427..430
FT                   /note="KNID -> N (in NS4)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066039"
FT   VARIANT         432..433
FT                   /note="Missing (in NS4)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066040"
FT   VARIANT         432
FT                   /note="W -> R (in NS4; dbSNP:rs267607080)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:19438935, ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030428"
FT   VARIANT         433
FT                   /note="E -> K (in NS4; dbSNP:rs397517147)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:19953625, ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030429"
FT   VARIANT         434
FT                   /note="G -> K (in NS4; requires 2 nucleotide substitutions;
FT                   dbSNP:rs730881048)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066041"
FT   VARIANT         434
FT                   /note="G -> R (in NS4; dbSNP:rs397517148)"
FT                   /evidence="ECO:0000269|PubMed:17143285,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030430"
FT   VARIANT         437
FT                   /note="I -> T (in NS4; dbSNP:rs397517150)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066042"
FT   VARIANT         441
FT                   /note="C -> Y (in NS4; dbSNP:rs727504295)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030431"
FT   VARIANT         477
FT                   /note="Q -> R (in NS4; dbSNP:rs730881044)"
FT                   /evidence="ECO:0000269|PubMed:20683980,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_064505"
FT   VARIANT         478
FT                   /note="P -> L (found in patients with Noonan syndrome;
FT                   dbSNP:rs1553356111)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066043"
FT   VARIANT         478
FT                   /note="P -> R (in NS4; dbSNP:rs1553356111)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066044"
FT   VARIANT         482
FT                   /note="G -> R (in NS4; dbSNP:rs1431574387)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066045"
FT   VARIANT         490
FT                   /note="L -> R (in NS4)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066046"
FT   VARIANT         497
FT                   /note="R -> Q (in NS4; one patient with Noonan syndrome
FT                   also carries a likely pathogenic mutation Ser-261 in RAF1;
FT                   the mutant protein cannot induce ERK1 phosphorylation;
FT                   dbSNP:rs371314838)"
FT                   /evidence="ECO:0000269|PubMed:20683980,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_064506"
FT   VARIANT         548
FT                   /note="S -> R (in NS4; dbSNP:rs397517149)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030432"
FT   VARIANT         549
FT                   /note="T -> K (in NS4; dbSNP:rs730881046)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066047"
FT   VARIANT         550
FT                   /note="L -> P (in NS4; dbSNP:rs397517153)"
FT                   /evidence="ECO:0000269|PubMed:17143282"
FT                   /id="VAR_030433"
FT   VARIANT         552
FT                   /note="R -> G (in NS4; increases the basal level of active
FT                   RAS; prolonges RAS activation after EGF stimulation and
FT                   enhances ERK activation; dbSNP:rs137852814)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19953625,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030434"
FT   VARIANT         552
FT                   /note="R -> K (in NS4; dbSNP:rs397517154)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030435"
FT   VARIANT         552
FT                   /note="R -> M (in NS4; dbSNP:rs397517154)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066048"
FT   VARIANT         552
FT                   /note="R -> S (in NS4; dbSNP:rs267607079)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030436"
FT   VARIANT         552
FT                   /note="R -> T (in NS4; dbSNP:rs397517154)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066049"
FT   VARIANT         554..558
FT                   /note="LDVTM -> K (in NS4)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066050"
FT   VARIANT         569
FT                   /note="L -> V (in dbSNP:rs200786705)"
FT                   /evidence="ECO:0000269|PubMed:19953625,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066051"
FT   VARIANT         623
FT                   /note="F -> I (in NS4; dbSNP:rs727505093)"
FT                   /evidence="ECO:0000269|PubMed:20673819"
FT                   /id="VAR_066052"
FT   VARIANT         655
FT                   /note="P -> L (in dbSNP:rs56219475)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:19953625,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030437"
FT   VARIANT         702
FT                   /note="Y -> H (in NS4; dbSNP:rs727505381)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:20683980"
FT                   /id="VAR_030438"
FT   VARIANT         708
FT                   /note="A -> T (in dbSNP:rs140811086)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066053"
FT   VARIANT         729
FT                   /note="W -> L (in NS4; promotes constitutive RAS activation
FT                   and enhances ERK activation)"
FT                   /evidence="ECO:0000269|PubMed:17143282"
FT                   /id="VAR_030439"
FT   VARIANT         733
FT                   /note="I -> F (in NS4; dbSNP:rs574088829)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030440"
FT   VARIANT         784
FT                   /note="I -> T (in a patient with Noonan syndrome;
FT                   dbSNP:rs1335137808)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066054"
FT   VARIANT         846
FT                   /note="E -> K (in NS4; dbSNP:rs397517159)"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:17143285, ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030441"
FT   VARIANT         894
FT                   /note="P -> R (in NS4; dbSNP:rs1367714753)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066055"
FT   VARIANT         977
FT                   /note="Q -> R"
FT                   /evidence="ECO:0000269|PubMed:17143282"
FT                   /id="VAR_030442"
FT   VARIANT         1011
FT                   /note="N -> S (in dbSNP:rs8192671)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066056"
FT   VARIANT         1131
FT                   /note="R -> K (in a patient with Noonan syndrome;
FT                   dbSNP:rs768113420)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066057"
FT   VARIANT         1140
FT                   /note="L -> I (in a patient with Noonan syndrome;
FT                   dbSNP:rs375550588)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066058"
FT   VARIANT         1257
FT                   /note="T -> A (in a patient with Noonan syndrome;
FT                   dbSNP:rs553805862)"
FT                   /evidence="ECO:0000269|PubMed:21387466"
FT                   /id="VAR_066059"
FT   VARIANT         1320
FT                   /note="H -> R"
FT                   /evidence="ECO:0000269|PubMed:17143282,
FT                   ECO:0000269|PubMed:21387466"
FT                   /id="VAR_030443"
FT   MUTAGEN         282
FT                   /note="C->R: Increases MAPK3 phosphorylation in response to
FT                   EGF stimulation."
FT                   /evidence="ECO:0000269|PubMed:17339331"
FT   MUTAGEN         1134
FT                   /note="S->A: Loss of phosphorylation, disruption of
FT                   interaction with YWHAB and YWHAE, and modest increase in
FT                   the magnitude and duration of EGF-induced MAPK1/3
FT                   phosphorylation; when associated with A-1161."
FT                   /evidence="ECO:0000269|PubMed:22827337"
FT   MUTAGEN         1161
FT                   /note="S->A: Loss of phosphorylation, disruption of
FT                   interaction with YWHAB and YWHAE, and modest increase in
FT                   the magnitude and duration of EGF-induced MAPK1/3
FT                   phosphorylation; when associated with A-1134."
FT                   /evidence="ECO:0000269|PubMed:22827337"
FT   TURN            13..15
FT                   /evidence="ECO:0007829|PDB:1Q9C"
FT   STRAND          19..23
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           24..34
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   STRAND          36..39
FT                   /evidence="ECO:0007829|PDB:1Q9C"
FT   HELIX           42..61
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           67..77
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           82..94
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   STRAND          100..102
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           107..118
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           124..151
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           159..168
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           172..175
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           201..224
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   TURN            225..227
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           228..232
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   TURN            234..236
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           239..246
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           249..268
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   STRAND          274..276
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           280..288
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   TURN            289..292
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           293..302
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           307..316
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           320..327
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           331..337
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           339..342
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           345..363
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           367..379
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           381..392
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           394..402
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           420..426
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   STRAND          429..431
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           437..439
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   STRAND          444..452
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   TURN            453..456
FT                   /evidence="ECO:0007829|PDB:1AWE"
FT   STRAND          459..473
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           480..482
FT                   /evidence="ECO:0007829|PDB:1AWE"
FT   STRAND          487..496
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   STRAND          500..503
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   STRAND          507..509
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   STRAND          512..516
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   TURN            519..521
FT                   /evidence="ECO:0007829|PDB:1AWE"
FT   STRAND          524..527
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           531..545
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   TURN            546..549
FT                   /evidence="ECO:0007829|PDB:1DBH"
FT   HELIX           564..567
FT                   /evidence="ECO:0007829|PDB:7AVL"
FT   TURN            572..574
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           576..578
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   TURN            583..585
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          586..588
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          590..592
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   TURN            594..596
FT                   /evidence="ECO:0007829|PDB:4URZ"
FT   STRAND          601..604
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           606..613
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          616..618
FT                   /evidence="ECO:0007829|PDB:5OVE"
FT   HELIX           621..630
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           631..633
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           637..648
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           657..664
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          665..667
FT                   /evidence="ECO:0007829|PDB:3KSY"
FT   HELIX           672..680
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           682..699
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           702..706
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           708..719
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           724..726
FT                   /evidence="ECO:0007829|PDB:6V9N"
FT   HELIX           727..742
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          764..766
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           771..773
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   TURN            776..778
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           781..797
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           801..803
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           805..810
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          811..813
FT                   /evidence="ECO:0007829|PDB:5OVH"
FT   HELIX           814..817
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           819..840
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           845..864
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           868..878
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           881..884
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           887..891
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           895..906
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           909..919
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           931..942
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          946..950
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          953..957
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           958..974
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           985..992
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   TURN            996..999
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   HELIX           1002..1016
FT                   /evidence="ECO:0007829|PDB:6V9M"
FT   STRAND          1020..1022
FT                   /evidence="ECO:0007829|PDB:7UKS"
SQ   SEQUENCE   1333 AA;  152464 MW;  C6B99CCA11A8DE45 CRC64;
     MQAQQLPYEF FSEENAPKWR GLLVPALKKV QGQVHPTLES NDDALQYVEE LILQLLNMLC
     QAQPRSASDV EERVQKSFPH PIDKWAIADA QSAIEKRKRR NPLSLPVEKI HPLLKEVLGY
     KIDHQVSVYI VAVLEYISAD ILKLVGNYVR NIRHYEITKQ DIKVAMCADK VLMDMFHQDV
     EDINILSLTD EEPSTSGEQT YYDLVKAFMA EIRQYIRELN LIIKVFREPF VSNSKLFSAN
     DVENIFSRIV DIHELSVKLL GHIEDTVEMT DEGSPHPLVG SCFEDLAEEL AFDPYESYAR
     DILRPGFHDR FLSQLSKPGA ALYLQSIGEG FKEAVQYVLP RLLLAPVYHC LHYFELLKQL
     EEKSEDQEDK ECLKQAITAL LNVQSGMEKI CSKSLAKRRL SESACRFYSQ QMKGKQLAIK
     KMNEIQKNID GWEGKDIGQC CNEFIMEGTL TRVGAKHERH IFLFDGLMIC CKSNHGQPRL
     PGASNAEYRL KEKFFMRKVQ INDKDDTNEY KHAFEIILKD ENSVIFSAKS AEEKNNWMAA
     LISLQYRSTL ERMLDVTMLQ EEKEEQMRLP SADVYRFAEP DSEENIIFEE NMQPKAGIPI
     IKAGTVIKLI ERLTYHMYAD PNFVRTFLTT YRSFCKPQEL LSLIIERFEI PEPEPTEADR
     IAIENGDQPL SAELKRFRKE YIQPVQLRVL NVCRHWVEHH FYDFERDAYL LQRMEEFIGT
     VRGKAMKKWV ESITKIIQRK KIARDNGPGH NITFQSSPPT VEWHISRPGH IETFDLLTLH
     PIEIARQLTL LESDLYRAVQ PSELVGSVWT KEDKEINSPN LLKMIRHTTN LTLWFEKCIV
     ETENLEERVA VVSRIIEILQ VFQELNNFNG VLEVVSAMNS SPVYRLDHTF EQIPSRQKKI
     LEEAHELSED HYKKYLAKLR SINPPCVPFF GIYLTNILKT EEGNPEVLKR HGKELINFSK
     RRKVAEITGE IQQYQNQPYC LRVESDIKRF FENLNPMGNS MEKEFTDYLF NKSLEIEPRN
     PKPLPRFPKK YSYPLKSPGV RPSNPRPGTM RHPTPLQQEP RKISYSRIPE SETESTASAP
     NSPRTPLTPP PASGASSTTD VCSVFDSDHS SPFHSSNDTV FIQVTLPHGP RSASVSSISL
     TKGTDEVPVP PPVPPRRRPE SAPAESSPSK IMSKHLDSPP AIPPRQPTSK AYSPRYSISD
     RTSISDPPES PPLLPPREPV RTPDVFSSSP LHLQPPPLGK KSDHGNAFFP NSPSPFTPPP
     PQTPSPHGTR RHLPSPPLTQ EVDLHSIAGP PVPPRQSTSQ HIPKLPPKTY KREHTHPSMH
     RDGPPLLENA HSS
//
